Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 19/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 15/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.48 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.47 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4535561 | 0.91 | PIK3CB (0.52) | PIK3CBPIK3CDPIK3CAPIK3R1PIK3CG | |
| SCHEMBL3990038 | 0.85 | PIK3CB (0.56) | PIK3CBPIK3CDPIK3CAPIK3R1PIK3CG | |
| SCHEMBL4525853 | 0.80 | PIK3CB (0.57) | PIK3CBPIK3CDPIK3CAPIK3R1PIK3CG | |
| SCHEMBL4515272 | 0.77 | PIK3CB (0.65) | PIK3CBPIK3CDPIK3CAPIK3R1PIK3CG | |
| SCHEMBL4533118 | 0.77 | PIK3CB (0.54) | PIK3CBPIK3CDPIK3CAPIK3R1PIK3CG | |
| SCHEMBL4520308 | 0.76 | PIK3CB (0.54) | PIK3CBPIK3CDPIK3CAPIK3R1PIK3CG | |
| SCHEMBL10153982 | 0.76 | PIK3CD (0.58) | PIK3CBPIK3CDPIK3CAPIK3R1PIK3CG | |
| SCHEMBL4530233 | 0.76 | PIK3CB (0.47) | PIK3CBPIK3CDPIK3CAPIK3R1PIK3CG | |
| SCHEMBL4532379 | 0.76 | PIK3CB (0.61) | PIK3CBPIK3CDPIK3CAPIK3R1PIK3CG | |
| SCHEMBL3994352 | 0.76 | PIK3CB (0.61) | PIK3CBPIK3CDPIK3CAPIK3R1PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325954-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PHENYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325954-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PHENYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | PIK3CA, MTOR, PIK3CD | PIK3CB 4/4885PIK3CD 3/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.